Lowering The 52 Week Low, Conatus Pharmaceuticals Inc (Nasdaq:CNAT) Finishing At $1.71

0
5
Stranded freeimages.com/stephie
Stranded freeimages.com/stephie

Conatus Pharmaceuticals Inc (Nasdaq:CNAT)

December 7th, 2018
Amidst falling markets Conatus Pharmaceuticals Inc fell $0.23 Friday, down 11.86%, closing at $1.71. As well as the drop in value, Conatus Pharmaceuticals Inc hit a new 52 week low of $1.52, breaking the previous low of $1.80 from earlier this month. Conatus Pharmaceuticals Inc swung 26.97% between high and low. Two technical ‘scores’ for companies to be aware of are the Altman Z1 and the Piotroski2 scores. CNAT scored rather low for both, which could be indicators of trouble down the road (the Altman Z-Score is -3.33, and the Piotroski Score is 2). Despite the drop in value, trading volumes were solid at 297% of normal which can indicate investor opportunities.

CNAT was outperformed by the rest of the Healthcare sector which went down only 2.51%.

Market Sectors

The market sectors were mixed Friday with a majority of the sectors trending down. Utilities saw the biggest increase of the day (0.40%), while Information Technology saw the biggest drop (3.53%). Healthcare has seen the biggest year-to-date gain at 9.38%. The biggest loss this year has been the Materials sector declining 15%.

Utilities saw the biggest turnaround from its 5-day performance of 2.89%, as it went up 0.40%. Real Estate saw a turn around from its 5-day performance of 1.28% trading down 1.44%.

Sector Breakdown

  • Utilities went up with a 0.40% change.
  • Energy went down with a -0.64% change.
  • Consumer Staples went down with a -1.29% change.
  • Real Estate went down with a -1.44% change.
  • Financials went down with a -1.84% change.
  • Communication Services went down with a -2.09% change.
  • Healthcare went down with a -2.51% change.
  • Materials went down with a -2.54% change.
  • Industrials went down with a -2.62% change.
  • Consumer Discretionary went down with a -3.08% change.
  • Information Technology went down with a -3.53% change.

Conatus Pharmaceuticals Inc Info

Conatus Pharmaceuticals Inc., a biotechnology company, focuses on the development and commercialization of novel medicines for the treatment of liver diseases in the United States. Its product candidates include Emricasan, an orally active pan-caspase protease inhibitor that is in Phase IIb clinical trials for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response; for patients with portal hypertension; for patients liver fibrosis caused by nonalcoholic steatohepatitis; and for liver function. The company was founded in 2005 and is headquartered in San Diego, California.

All amounts in USD unless otherwise indicated

(1) The Altman Z-Score calculation was first published in 1968 by Edward I. Altman, and is used for predicting the probability that a firm will go into bankruptcy within two years. An Altman Z-Score below 1.8 (Remember that Conatus Pharmaceuticals Inc’s score is -3.33) is the trigger to be alert for this situation. Some analysts believe this score is less relevant for some companies, in particular companies operating to accumulate users that may run at huge losses to scale up.

(2) The Piotrosky score is used to determine the best value stocks with nine being the best and zero being the worst. It is based on specific aspects of the company’s financial statements, such as positive net income, operating cash flow and asset turnover ratio. A score 0 0 is the worst (Conatus Pharmaceuticals Inc’s score is 2), and 9 is the best.

CNAT daily update
CNAT daily update


Media Gazelle Inc (MG), a Nevada Corporation, owns and operates the online brand US Tribune News. MG does not offer financial advise, and is not a registered broker/dealer/analyst/adviser, holds no investment licenses, and may not sell, offer to sell or offer to buy any security. MG’s market updates, news are not a solicitation or recommendation to buy, sell or hold securities. MG shall not be held liable for any investment losses you may incur by using the information provided, this includes you trading the stocks mentioned on our sites. We recommend you talk to a financial adviser before trading any securities or taking any action based upon information on this site. MG does not guarantee the accuracy of the article.

This site uses Akismet to reduce spam. Learn how your comment data is processed.